Human ADRA2A Stable Cell Line - BV2

The ADRA2A gene encodes the α-2A adrenergic receptor, a critical and highly conserved member of the G protein-coupled receptor (GPCR) superfamily. Upon activation by endogenous catecholamines—such as norepinephrine and epinephrine—this receptor primarily couples with the Gi and Go subfamilies of heterotrimeric G proteins. This pivotal intracellular coupling process initiates a cascade of signal transduction events, most notably the direct inhibition of adenylyl cyclase, which subsequently leads to a significant reduction in intracellular cyclic adenosine monophosphate (cAMP) levels. Furthermore, activation of the α-2A adrenergic receptor modulates various ion channels—including the activation of inwardly rectifying potassium channels and the inhibition of voltage-gated calcium channels—thereby inducing cellular hyperpolarization and reducing overall neuronal excitability. Within the central nervous system (CNS), it functions predominantly as a presynaptic autoreceptor in key brain regions, such as the locus coeruleus and the prefrontal cortex. Beyond its central role in neurotransmitter modulation, the α-2A adrenergic receptor plays a foundational role in mediating a wide spectrum of physiological and behavioral processes. These processes range from the central regulation of systemic blood pressure, pain perception, and pain management to sedation, working memory, and complex executive cognitive functions. The ADRA2A gene and its corresponding receptor are directly implicated in numerous human pathological conditions, spanning from cardiovascular hypertension to severe neuropsychiatric disorders such as depression, anxiety disorders, and attention-deficit/hyperactivity disorder (ADHD).

The BV2 parental cell line is an extensively characterized and widely utilized immortalized murine microglial cell line; it effectively recapitulates the phenotypic characteristics and functional attributes of primary microglia—the principal resident immune macrophages of the mammalian CNS. By stably integrating the human ADRA2A gene into these microglial cells, this engineered product provides researchers with a robust, consistent, and physiologically relevant experimental model to deeply investigate the precise mechanisms of interaction between adrenergic signaling cascades and neuroinflammatory responses. One of the primary applications of the human ADRA2A stable cell line (based on the BV2 cell line) lies in its extensive utility for high-throughput drug screening. Scientists can leverage this reliable platform—utilizing standard biochemical assays such as cyclic adenosine monophosphate (cAMP) accumulation measurements, intracellular calcium flux detection, and downstream receptor internalization assays—to rapidly identify, precisely characterize, and validate novel agonists, antagonists, and allosteric modulators targeting the human ADRA2A receptor.